Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Amplitude Inc (AMPL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Amplitude Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $224 (market cap $29.60B), while Amplitude Inc trades at $12.56 (market cap $1.59B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 18.6× Amplitude Inc's market cap, and Amplitude Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | AMPL | |
|---|---|---|
Market Cap | $29.60B | $1.59B |
Sector | Health | Technology |
52-Week High | $491.22 | $12.69 |
52-Week Low | $205.48 | $5.61 |
Enterprise Value | $27.56B | $1.45B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
AMPL trades at $12.38, up 1.56% with bullish technical signals from moving averages and ADX indicators. The company shows strong revenue growth reaching $343M in 2025 with a 72% gross margin, though it continues to report net losses. Recent Q2 2026 results missed EPS expectations but beat revenue estimates, with management highlighting AI analytics platform growth and enterprise customer expansion as key drivers.
While analyst consensus remains bullish with 67% buy ratings and a $12.08 price target, investors face execution risks from persistent losses, negative cash flow, and ongoing fraud investigations. The stock's valuation appears stretched at 11.6x book value, requiring successful monetization of AI initiatives to justify current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Amplitude Inc
Amplitude Inc is pioneering a new category of software called digital optimization. The company's digital optimization system serves as the command center for businesses to connect digital products to business outcomes.
Read more on AMPL →
